The IHGSC and Celera researchers combined the DNA model they were interested in sequencing, containing DNA polymerase, a unique DNA primer, free bases of desoxynucleotides (dATP, dCTP, dGTP and dTTP) and a rare mixture of fluorescent labeled dideoxynucleotide bases (ddATP, ddCTP, ddGTP and ddTTP), each marked with a different color and ending the new DNA synthesis; As soon as they have been incorporated into the end of a growing strand of DNA. The mixture was first heated to denature the DNA strand of the template; This was followed by a cooling step so that the first of the DNA could shine. After the glow of primeur, the polymerase synthesized a complementary strand of DNA. The model would increase until a dideoxynucleotide (ddNTP) base is installed; the conditions were such that this happened by chance along the length of the synthesized DNA strands. In the end, the researchers retained a mixture of synthesized DNA strands, different in length of a single nucleotide, marked at their 3′ end with the color of the dye molecule associated with ddNTP (Figure 6b). Whole genome sequencing is performed by Illumina Laboratory Services (ILS) in Cambridge, UK, which works under Medical Laboratory accreditation (ISO 15189) with NovaSeq 6000, BaseSpace Sequence Hub and Illumina analysis tools. The availability of 100,000 genomes was a huge achievement that would not have been possible without the partnership of the NHS and the academic, clinical and commercial community. We are pleased to develop our relationship with Illumina, which has been an invaluable partner since 2014, and to continue to support the accelerated introduction of advanced genomic medicine into the NHS. The UK is already in the lead, but this agreement builds on a solid foundation by further demonstrating the UK`s commitment to supporting the NHS`s provision of truly personalised procurement. By offering competitive prices for our sequencing services, BGI genomiQa helps to perform genome-entire analysis for patients. By collaborating with genomiQa, researchers and physicians can use genome-whole analysis to develop potential new treatments and support the best patient outcomes, such as the Immunotherapy Outcomes Predication project, which we are working on together2. » Celera`s methods of the entire genome and regional chromosomal assasy were independent of one another, allowing for direct comparison of the data.